Join to View Full Profile
1100 Fairview Avenue N.Seattle, WA 98109
Phone+1 206-667-1912
Dr. Paulovich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2004
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1998 - 2000
University of Washington School of MedicineClass of 1998
Certifications & Licensure
WA State Medical License 2004 - 2027
MA State Medical License 2002 - 2005
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2012
Publications & Presentations
PubMed
- 1 citationsThe DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study.Timothy A Yap, Patricia LoRusso, Rowan E Miller, Rebecca Kristeleit, Amanda G Paulovich
British Journal of Cancer. 2025-08-01 - Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.Jasmine Naru, Megan Othus, ChenWei Lin, Melinda A Biernacki, Marie Bleakley
Ejhaem. 2024-12-01 - 22 citationsNeoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin
Cancer Cell. 2024-11-11
Press Mentions
Combination Therapy Shows Promising Results in Treating Stage 3 MelanomaOctober 31st, 2024- Pediatric Brain Tumor Proteomics Highlight Possible Treatment Targets, BiomarkersNovember 25th, 2020
- First Large-Scale Proteogenomic Analysis Offers Insights into Pediatric Brain TumorsNovember 25th, 2020
- Join now to see all
Grant Support
- Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trialsFRED HUTCHINSON CANCER CENTER2025–2030
- Clinical translation of a NexGen platform for quantifying protein networks in human biospecimensFRED HUTCHINSON CANCER CENTER2019–2029
- Breast-cancer focused biomarker characterization center employing targeted mass spec assays in a CLIA environmentFRED HUTCHINSON CANCER CENTER2023–2028
- Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapiesFRED HUTCHINSON CANCER CENTER2022–2027
- Proteo-Genomic Discovery, Prioritization And Verification Of Cancer BiomarkersNational Cancer Institute2011
- Population-Based Study Of DNA Damage Response Markers Of Prognosis In Breast CancNational Cancer Institute2010–2011
- Minimizing Mass Panic With Saliva Tests For Radiation ExposureNational Institute Of Allergy And Infectious Diseases2008–2011
- Cross-Species Network Approach To Predict Epistatic Cancer Susceptibility GenesNational Cancer Institute2008–2011
- Phenotype-Based Approach To FIND Gene Interactions Underlying Breast Cancer RiskNational Cancer Institute2007–2011
- Measurement Of Cancer-Associated Biomarker Proteins In Complex Biological SamplesNational Cancer Institute2009–2010
- Protein Biomarker DosimetryNational Institute Of Allergy And Infectious Diseases2005–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
